AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21495900 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g E. officinalis powder per day
Number of subjects: 0
Study 21495900 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g E. officinalis powder per day
Number of subjects: 0
Study 19535707 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine administered 30 min before 2-chloroprocaine anesthesia (n = 29)
Number of subjects: 87
Study 19535707 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine administered after 2-chloroprocaine anesthesia (n = 30)
Number of subjects: 87
Study 19535707 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine administered after lidocaine anesthesia (n = 28)
Number of subjects: 87
Study 19535707 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain scores in the postanesthesia care unit
Number of subjects: 87
Study 19535707 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain scores on admission to the postpartum unit
Number of subjects: 87
Study 19535707 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental morphine equivalents administered in the first 48 h
Number of subjects: 87
Study 19535707 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid-related side effects
Number of subjects: 87
Study 17438515 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen-containing oral contraceptives
Number of subjects: 0
Study 17438515 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen treatment
Number of subjects: 0
Study 17438515 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone therapy
Number of subjects: 0
Study 17438515 — intervention group
Group type: COMPARATOR
Intervention: Delayed hormone therapy
Number of subjects: 0
Study 15110204 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy administered to 134 patients (12%)
Number of subjects: 1153
Study 15110204 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy after propensity score analyses
Number of subjects: 1153
Study 11180010 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant interleukin-10 administered subcutaneously over 6 weeks
Number of subjects: 14
Study 11180010 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant interleukin-10
Number of subjects: 14
Study 9274063 — intervention group
Group type: EXPERIMENTAL
Intervention: Iris 3000 foam mattress overlays (n = 20)
Number of subjects: 40
Study 9274063 — intervention group
Group type: COMPARATOR
Intervention: MAXIFLOAT foam mattress replacements (n = 20)
Number of subjects: 40
Study 8092234 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term down-regulation for 2 to 7 months followed by human menopausal gonadotropin and human chorionic gonadotropin
Number of subjects: 84
Study 8092234 — intervention group
Group type: COMPARATOR
Intervention: Control group with short protocol using gonadotropin-releasing hormone agonist followed by human menopausal gonadotropin and human chorionic gonadotropin
Number of subjects: 84
Study 3277827 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY m 1099
Number of subjects: 9
Study 3277827 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY o 1248
Number of subjects: 9
Study 3277827 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY m 1099 and BAY o 1248
Number of subjects: 9
Study 3277827 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 31574262 — intervention group
Group type: EXPERIMENTAL
Intervention: QuadraLite face mask
Number of subjects: 48
Study 31574262 — intervention group
Group type: COMPARATOR
Intervention: Air cushion face mask
Number of subjects: 48
Study 28445632 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine plus sertraline
Number of subjects: 258
Study 28445632 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine plus placebo
Number of subjects: 258
Study 25901426 — intervention group
Group type: EXPERIMENTAL
Intervention: Involved-field radiotherapy
Number of subjects: 602
Study 25901426 — intervention group
Group type: COMPARATOR
Intervention: No further therapy
Number of subjects: 602
Study 24190112 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel (80 mg/m² on days 1, 8, and 15, every 4 weeks)
Number of subjects: 219
Study 24190112 — intervention group
Group type: COMPARATOR
Intervention: Irinotecan (150 mg/m² on days 1 and 15, every 4 weeks)
Number of subjects: 219
Study 24190112 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Number of subjects: 219
Study 24190112 — intervention group
Group type: COMPARATOR
Intervention: Irinotecan
Number of subjects: 219
Study 21944095 — intervention group
Group type: EXPERIMENTAL
Intervention: Watchful waiting
Number of subjects: 1230
Study 21944095 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed treatment after initially waiting
Number of subjects: 1230
Study 18308781 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine
Number of subjects: 285
Study 16848646 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (50-200 mg/day)
Number of subjects: 326
Study 16848646 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 326
Study 12707158 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion of lactated Ringer's solution 40 mL/kg
Number of subjects: 12
Study 12707158 — intervention group
Group type: COMPARATOR
Intervention: Background infusion of lactated Ringer's solution 5 mL/kg
Number of subjects: 12
Study 10865416 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking (smokers)
Number of subjects: 40
Study 10865416 — intervention group
Group type: COMPARATOR
Intervention: Non-smoking (non-smokers)
Number of subjects: 40
Study 9181530 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucocyte (Le) IFN-alpha
Number of subjects: 69
Study 9181530 — intervention group
Group type: COMPARATOR
Intervention: Control (second course of the same IFN-alpha)
Number of subjects: 69
Study 1302572 — intervention group
Group type: EXPERIMENTAL
Intervention: MammaCare training technique
Number of subjects: 101
Study 1302572 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentric circle training technique
Number of subjects: 101
Study 1302572 — intervention group
Group type: COMPARATOR
Intervention: Baseline assessment
Number of subjects: 101
Study 4016830 — intervention group
Group type: EXPERIMENTAL
Intervention: Mezlocillin (5-gm dose administered intravenously 30 minutes before surgery)
Number of subjects: 0
Study 4016830 — intervention group
Group type: COMPARATOR
Intervention: Placebo (administered intravenously 30 minutes before surgery)
Number of subjects: 0
Study 4016830 — intervention group
Group type: EXPERIMENTAL
Intervention: Mezlocillin
Number of subjects: 0
Study 29766275 — intervention group
Group type: EXPERIMENTAL
Intervention: Cough Reflex Testing (CRT)
Number of subjects: 488
Study 29766275 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (bedside assessment)
Number of subjects: 488
Study 27686346 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iron
Number of subjects: 140
Study 27686346 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 24239600 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyangsa-Pyeongwi san (HPS) 9.68g at once, three times daily for 4 weeks
Number of subjects: 170
Study 24239600 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 170
Study 21869730 — intervention group
Group type: EXPERIMENTAL
Intervention: enalapril FA tablet (10 : 0.4 mg, low‐FA group)
Number of subjects: 480
Study 21869730 — intervention group
Group type: EXPERIMENTAL
Intervention: enalapril FA tablet (10 : 0.8 mg, high‐FA group)
Number of subjects: 480
Study 21869730 — intervention group
Group type: COMPARATOR
Intervention: enalapril only (10 mg, control group)
Number of subjects: 480
Study 20569064 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy during tuberculosis therapy
Number of subjects: 0
Study 20569064 — intervention group
Group type: COMPARATOR
Intervention: Tuberculosis therapy alone
Number of subjects: 0
Study 18280582 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient treatment for schizophrenia or schizophreniform disorders
Number of subjects: 200
Study 16172596 — intervention group
Group type: EXPERIMENTAL
Intervention: Almond milk (Group A, n=26)
Number of subjects: 52
Study 16172596 — intervention group
Group type: COMPARATOR
Intervention: Soy-based formula (Group B, n=13)
Number of subjects: 52
Study 16172596 — intervention group
Group type: COMPARATOR
Intervention: Protein hydrolysate-based formula (n=13)
Number of subjects: 52
Study 14653235 — intervention group
Group type: EXPERIMENTAL
Intervention: Bougienage and omeprazole (20 mg/day for 12 months)
Number of subjects: 100
Study 14653235 — intervention group
Group type: EXPERIMENTAL
Intervention: Bougienage and ranitidine (300 mg/day for 12 months)
Number of subjects: 100
Study 14653235 — intervention group
Group type: COMPARATOR
Intervention: Only bougienage
Number of subjects: 100
Study 11130802 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone counseling
Number of subjects: 1443
Study 11130802 — intervention group
Group type: EXPERIMENTAL
Intervention: Mail counseling
Number of subjects: 1443
Study 11130802 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 1443
Study 9020535 — intervention group
Group type: EXPERIMENTAL
Intervention: Multitest CMI
Number of subjects: 20
Study 9020535 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4/CD8 ratio
Number of subjects: 20
Study 1412119 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (1.6 mg inhaled per day for three weeks)
Number of subjects: 10
Study 1412119 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (40 mg oral per day for eight days)
Number of subjects: 10
Study 1412119 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 1412119 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 10
Study 1412119 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium
Number of subjects: 10
Study 6443771 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefsulodin
Number of subjects: 29
Study 6443771 — intervention group
Group type: COMPARATOR
Intervention: Tobramycin
Number of subjects: 29
Study 6443771 — intervention group
Group type: COMPARATOR
Intervention: Ticarcillin
Number of subjects: 29
Study 30988711 — intervention group
Group type: EXPERIMENTAL
Intervention: BIOF2 treatment (intra-articular BIOF2 application at 0, 1 and 2 months)
Number of subjects: 212
Study 30988711 — intervention group
Group type: EXPERIMENTAL
Intervention: BIOF2 treatment (intra-articular BIOF2 application at 0, 1 and 2 months) excluding patients with class 2 obesity or malalignment
Number of subjects: 212
Study 30988711 — intervention group
Group type: COMPARATOR
Intervention: Usual medical care (paracetamol/NSAIDs and general care provided by the family physician)
Number of subjects: 212
Study 30323196 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 validated lncRNAs
Number of subjects: 500
Study 30323196 — intervention group
Group type: EXPERIMENTAL
Intervention: Training set
Number of subjects: 500
Study 30323196 — intervention group
Group type: EXPERIMENTAL
Intervention: Validation set
Number of subjects: 500
Study 30323196 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-expression network
Number of subjects: 500
Study 30323196 — intervention group
Group type: EXPERIMENTAL
Intervention: KEGG pathway enrichment analysis
Number of subjects: 500
Study 27327233 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental protocol (15 s CPR during and after charging of the AED, immediate CPR resumption after defibrillation)
Number of subjects: 456
Study 27327233 — intervention group
Group type: COMPARATOR
Intervention: Control protocol (post-shock analysis and pulse check as per Guidelines 2000)
Number of subjects: 456
Study 27327233 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental protocol
Number of subjects: 456
Study 27327233 — intervention group
Group type: COMPARATOR
Intervention: Control protocol
Number of subjects: 456
Study 23336207 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional PPD antigen
Number of subjects: 40
Study 23336207 — intervention group
Group type: COMPARATOR
Intervention: Intralesional saline (control)
Number of subjects: 40
Study 22406697 — intervention group
Group type: EXPERIMENTAL
Intervention: Dehydration trial (2.5% body weight loss)
Number of subjects: 12
Study 22406697 — intervention group
Group type: COMPARATOR
Intervention: Euhydration trial (rested state)
Number of subjects: 12
Study 20195744 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovarian function suppression plus 5 years of tamoxifen with anthracycline-based chemotherapy
Number of subjects: 174
Study 20195744 — intervention group
Group type: COMPARATOR
Intervention: Ovarian function suppression plus 5 years of tamoxifen without chemotherapy (endocrine therapy alone)
Number of subjects: 174
Study 20195744 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant! estimate for endocrine therapy alone
Number of subjects: 174
Study 20195744 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant! estimate for chemoendocrine therapy
Number of subjects: 174
Study 17919634 — intervention group
Group type: EXPERIMENTAL
Intervention: Gut-directed hypnotherapy (HT) consisting of 6 sessions over a 3-month period.
Number of subjects: 53
Study 17919634 — intervention group
Group type: COMPARATOR
Intervention: Standard medical therapy (SMT) with 6 sessions of supportive therapy.
Number of subjects: 53
Study 11674922 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (sublingual immunotherapy with a biologically standardised extract of three pollens)
Number of subjects: 30
Study 11674922 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 11674922 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (sublingual immunotherapy) during the second year
Number of subjects: 30
Study 11674922 — intervention group
Group type: COMPARATOR
Intervention: Control group (treated only with drugs)
Number of subjects: 30
Study 9272652 — intervention group
Group type: EXPERIMENTAL
Intervention: Falling blood glucose levels during cognitive tasks
Number of subjects: 0
Study 8048681 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual education and medical consultations for adolescents with emphasis on contraception
Number of subjects: 1010
Study 8048681 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced abortions as a pregnancy outcome
Number of subjects: 1010
Study 8048681 — intervention group
Group type: EXPERIMENTAL
Intervention: Low level of effective contraceptive use
Number of subjects: 1010
Study 2882607 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen sodium (550 mg)
Number of subjects: 52
Study 2882607 — intervention group
Group type: COMPARATOR
Intervention: Propoxyphene napsylate with acetaminophen (PN/A, 100 mg with 650 mg)
Number of subjects: 52
Study 31679865 — intervention group
Group type: EXPERIMENTAL
Intervention: MF59®‐adjuvanted trivalent influenza vaccine (aTIV; Fluad®)
Number of subjects: 196
Study 31679865 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest dosage of antigen in combination with the highest dosage of adjuvant
Number of subjects: 196
Study 31679865 — intervention group
Group type: COMPARATOR
Intervention: Modified aTIV formulations
Number of subjects: 196
Study 28940259 — intervention group
Group type: EXPERIMENTAL
Intervention: Guselkumab
Number of subjects: 1829
Study 28940259 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1829
Study 28940259 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab
Number of subjects: 1829
Study 26763271 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (1000 impulses and 2.1 bar)
Number of subjects: 40
Study 26763271 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid injection
Number of subjects: 40
Study 24074486 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin + Clopidogrel dual therapy
Number of subjects: 546
Study 24074486 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 546
Study 24074486 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 546
Study 24074486 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 546
Study 24074486 — intervention group
Group type: EXPERIMENTAL
Intervention: Study group (patients on anti-platelet therapy)
Number of subjects: 546
Study 24074486 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual therapy
Number of subjects: 546
Study 23159587 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20649945 — intervention group
Group type: EXPERIMENTAL
Intervention: Topically applied pure lavender oil (1 ml of 30% high strength essential lavender oil)
Number of subjects: 0
Study 20649945 — intervention group
Group type: COMPARATOR
Intervention: Placebo oil (jojoba oil only)
Number of subjects: 0
Study 18207205 — intervention group
Group type: EXPERIMENTAL
Intervention: Astringent solution (5 g L(‐1) tannic acid in distilled water)
Number of subjects: 12
Study 18207205 — intervention group
Group type: EXPERIMENTAL
Intervention: Distilled drinking water
Number of subjects: 12
Study 18207205 — intervention group
Group type: EXPERIMENTAL
Intervention: Sweet solution (40 g L(‐1) sugar in mango tea with no tannins)
Number of subjects: 12
Study 18207205 — intervention group
Group type: COMPARATOR
Intervention: Mouth dried with air for 35 s
Number of subjects: 12
Study 18207205 — intervention group
Group type: COMPARATOR
Intervention: Mouth not dried (waiting for equal period of time)
Number of subjects: 12
Study 16415706 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-dose group
Number of subjects: 34
Study 16415706 — intervention group
Group type: COMPARATOR
Intervention: Fixed-dose group
Number of subjects: 34
Study 12406840 — intervention group
Group type: EXPERIMENTAL
Intervention: Autotitrating CPAP
Number of subjects: 44
Study 11058797 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed sleep phase syndrome (DSPS) patients
Number of subjects: 28
Study 11058797 — intervention group
Group type: EXPERIMENTAL
Intervention: Non‐24‐h sleep‐wake syndrome (non‐24) patients
Number of subjects: 28
Study 11058797 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 28
Study 8840101 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet
Number of subjects: 132
Study 8840101 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulphonylurea
Number of subjects: 132
Study 8840101 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin therapy
Number of subjects: 132
Study 1632166 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (0.3 mg) + bupivacaine (20 mg)
Number of subjects: 30
Study 1632166 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative naloxone infusion (1 microgram/kg/h over 12 h, 0.25 micrograms/kg/h over the next 12 h) + bupivacaine (20 mg) + morphine (0.3 mg)
Number of subjects: 30
Study 1632166 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine (20 mg)
Number of subjects: 30
Study 31539267 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine-learning models for objective response (OR)
Number of subjects: 17
Study 31539267 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine-learning models for progression-free survival (PFS)
Number of subjects: 17
Study 31539267 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine-learning models for overall survival (OS)
Number of subjects: 17
Study 28215413 — intervention group
Group type: EXPERIMENTAL
Intervention: SBP/RAP ratio <11
Number of subjects: 195
Study 28215413 — intervention group
Group type: EXPERIMENTAL
Intervention: SBP/RAP ratio <8
Number of subjects: 195
Study 28215413 — intervention group
Group type: EXPERIMENTAL
Intervention: SBP/RAP
Number of subjects: 195
Study 28215413 — intervention group
Group type: COMPARATOR
Intervention: RAP
Number of subjects: 195
Study 28215413 — intervention group
Group type: COMPARATOR
Intervention: SBP
Number of subjects: 195
Study 26260354 — intervention group
Group type: EXPERIMENTAL
Intervention: S. boulardii 250 mg
Number of subjects: 100
Study 26260354 — intervention group
Group type: EXPERIMENTAL
Intervention: S. boulardii 250 mg plus BS 524 mg
Number of subjects: 100
Study 26260354 — intervention group
Group type: EXPERIMENTAL
Intervention: BS 524 mg
Number of subjects: 100
Study 26260354 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 25551571 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon beta-1a every 2 weeks
Number of subjects: 1512
Study 25551571 — intervention group
Group type: COMPARATOR
Intervention: peginterferon beta-1a every 4 weeks
Number of subjects: 1512
Study 25551571 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1512
Study 23270444 — intervention group
Group type: EXPERIMENTAL
Intervention: normoxia + vitamin C
Number of subjects: 24
Study 23270444 — intervention group
Group type: EXPERIMENTAL
Intervention: hypoxia + vitamin C
Number of subjects: 24
Study 23270444 — intervention group
Group type: COMPARATOR
Intervention: normoxia control
Number of subjects: 24
Study 23270444 — intervention group
Group type: COMPARATOR
Intervention: hypoxia control
Number of subjects: 24
Study 19362455 — intervention group
Group type: EXPERIMENTAL
Intervention: Bitter melon (55 ml/24h)
Number of subjects: 25
Study 19362455 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone (4 mg/24h)
Number of subjects: 25
Study 19362455 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 25
Study 18500525 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 ml of oral contrast agent
Number of subjects: 6
Study 18500525 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 ml of oral contrast agent
Number of subjects: 6
Study 18500525 — intervention group
Group type: EXPERIMENTAL
Intervention: 450 ml of oral contrast agent
Number of subjects: 6
Study 15509637 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone enanthate (TE, 100 mg im weekly) + levonorgestrel (LNG, 125 microg orally daily)
Number of subjects: 22
Study 15509637 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone enanthate (TE, 100 mg im weekly) + levonorgestrel (LNG, 125 microg orally daily) + dutasteride (0.5 mg orally daily)
Number of subjects: 22
Study 15509637 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone enanthate (TE, 100 mg im weekly) + acyline (300 microg/kg sc every 2 wk)
Number of subjects: 22
Study 15509637 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone enanthate (TE, 100 mg im weekly) + levonorgestrel (LNG, 125 microg orally daily) + acyline (300 microg/kg sc every 2 wk)
Number of subjects: 22
Study 12523585 — intervention group
Group type: EXPERIMENTAL
Intervention: O 20 mg, clarithromycin (C) 250 mg, metronidazole (M) 500 mg (O.C.M)
Number of subjects: 426